Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.
about
Angiogenesis in Inflammatory Bowel DiseaseTargeting angiogenesis in squamous non-small cell lung cancerExpression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosaNo association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer.(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathwayAssessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein arrayVEGF receptor expression decreases during lung development in congenital diaphragmatic hernia induced by nitrofenPRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling.Medicinal plants and cancer chemoprevention.Antitumor and antiangiogenic activities of anti-vascular endothelial growth factor hairpin ribozyme in human hepatocellular carcinoma cell cultures and xenografts.Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Targeting angiogenesis with integrative cancer therapies.The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.Role of genetic polymorphisms in tumour angiogenesisTumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.Therapies directed at vascular endothelial growth factor.Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease.The effect of antivascular endothelial growth factor on the development of adhesion formation in laparotomized rats: experimental study.Molecular targets in the inhibition of angiogenesis.A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor GrowthThrombospondin-1 and VEGF in inflammatory bowel diseaseA Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.Angiogenesis in upper tract urothelial carcinoma associated with Balkan endemic nephropathy.ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma.Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?Inhibition of angiogenesis in the treatment of non-small cell lung cancer.Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy.Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.Molecular biological challenges in he treatment of esophageal adenocarcinoma.A new dawn for the use of traditional Chinese medicine in cancer therapy.Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor aResidual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.Placental ischemia and breast cancer risk after preeclampsia: tying the knot.MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma
P2860
Q26769945-5B69AB06-9839-4677-A4B4-3D17134DFF67Q26861341-2709C1E5-7FEC-4F16-81C1-367C99564A77Q28246673-6A6012B9-D012-483A-9686-614896AABD62Q33576258-078775F5-F6FA-4B0B-B72C-991ED3C12D7BQ33590458-AC9A9915-134A-43AA-A845-E0A45A49DBEFQ33634757-DBCFC38B-12A2-4DDE-B94D-E9844AC0337AQ33688120-E4C6F03B-FC2C-4C3B-BD96-E177938A78F2Q33732309-C604798E-C06A-4D23-A2E8-F96D86EB920BQ33826204-A90E0880-4103-4CCA-861A-974AAC84AD30Q34162937-B5ED67B5-F9BB-4578-A4AC-F457D15CBBA6Q34382968-7E36EB60-A8BF-406D-8678-3DA4DA0C2D5DQ34450520-D6C10B30-0868-49CF-BAE0-38F74712E95BQ34495463-B3E5A399-6B12-4EC5-91B4-E668106849CDQ34572068-6E8AA5E0-C940-44FE-89AF-87C02A10A24BQ34981278-D947993D-7D98-4B84-895F-FF1C5AA069D1Q35010488-AB8FE06F-B1C4-43BE-B008-4CDFA1B7ECDEQ35011885-8583ABF4-A3C0-406B-A5A4-1030688317FDQ35076287-1AF05B9D-3188-48D3-AE1C-85630C0015ECQ35081469-56921EE8-D2B6-4355-81B6-BECCFC77470CQ35094273-B5703F24-DE46-4DFD-878C-2BFD42B50639Q35186667-B28E6E39-4744-4B02-806C-FE74E0064E56Q35216723-4F63DFE4-9E58-4184-B98F-54EDEE9ABDB2Q35251663-F6609BB2-AEDD-432B-881E-14575D6B313EQ35720513-47828E8C-C9F3-407D-81F9-A3BDBA952188Q35836792-EB8A5515-6E24-4372-A78A-CF2D0194C63EQ35840331-75F14C7E-F3E4-4980-A174-C52EF9B0064DQ36224953-3ACF1247-4FF2-44DF-8388-9F9DFF45AD31Q36416481-44F45812-FE42-4AD7-898A-E09E4702BC6DQ36478084-23A1F5F3-935C-423B-9504-F7E313E9FFECQ36616962-E9E9CA5F-AD9D-4753-957C-8FF3C8C233F3Q36825153-2E817018-2AC2-4041-9BAC-1465F59FEB15Q36950548-C3F17EA9-AB95-445E-8ECC-12653D562DE6Q36986849-271D7D01-19F0-4ADF-BDFD-0F98A14343C5Q37002943-7F4C4F21-E4D3-403E-87C2-DBA73F04B7F6Q37345996-090FC435-1DF9-479E-9626-35F25469A4BAQ37418257-C701B8D8-EC5C-43EC-B048-04A494FC041AQ37422370-840988EC-9A4B-4398-9CC4-F10DE9E8E779Q37450606-6AD01FD0-708C-48DF-8460-17B89F817461Q37483999-B88F827B-68A5-4369-A2E3-A2A2CF819F30Q37671418-D116AB7A-6C26-4BE1-8417-24A7D043E547
P2860
Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Vascular endothelial growth fa ...... and therapeutic implications.
@ast
Vascular endothelial growth fa ...... and therapeutic implications.
@en
Vascular endothelial growth fa ...... and therapeutic implications.
@nl
type
label
Vascular endothelial growth fa ...... and therapeutic implications.
@ast
Vascular endothelial growth fa ...... and therapeutic implications.
@en
Vascular endothelial growth fa ...... and therapeutic implications.
@nl
prefLabel
Vascular endothelial growth fa ...... and therapeutic implications.
@ast
Vascular endothelial growth fa ...... and therapeutic implications.
@en
Vascular endothelial growth fa ...... and therapeutic implications.
@nl
P2093
P1433
P1476
Vascular endothelial growth fa ...... and therapeutic implications.
@en
P2093
P304
P356
10.1016/S1470-2045(01)00556-3
P577
2001-11-01T00:00:00Z